Has Bert Oneil, MD received payments from drug or device companies?

Yes. Drug and device makers reported $88,520 in general payments to Bert Oneil, MD across 126 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Bert Oneil, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Bert Oneil, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Bert Oneil, MD

Medical Oncology · Indianapolis, INNPI 1588724199

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (54.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by AstraZeneca at 57.6% of the total. 2025 is the largest year on record at $25,804, 2.2 times the $11,681 reported in 2019. Among medical oncology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$88,520in general payments, 2019–2025

Across 126 payments — averaging $702.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$51K
Eli Lilly$16K
Amgen$11K
Gilead$4K
Array Biopharma Inc$3K
Seagen Inc.$1K
plus $2K from 14 others

$7,564,869in research payments, 2019–2025

Across 876 payments — averaging $8635.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pfizer$1.6M
AbbVie$1.5M
Exelixis Inc.$1.2M
Amgen$973K
Seagen Inc.$684K
Merck$343K
plus $1.2M from 14 others

What the payments were for

Consulting fees$30,77135%
Speaking & faculty fees$48,11554%
Travel & lodging$5,4696%
Food & beverage$4,1665%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	45	$50,992
Eli Lilly	12	$16,065
Amgen	22	$11,337
Gilead	6	$4,125
Array Biopharma Inc	2	$2,700
Seagen Inc.	2	$1,412
Tempus AI, Inc	6	$426
Exelixis Inc.	6	$371
Daiichi Sankyo Inc.	5	$220
Genentech USA, Inc.	2	$150
Johnson & Johnson	1	$144
Janssen Scientific Affairs, LLC	6	$142
Novartis	1	$125
Genmab U.S., Inc.	1	$106
Genentech, Inc.	2	$63
Merck	3	$60
Ipsen Biopharmaceuticals, Inc	1	$27
Pharmaessentia USA Corporation	1	$21
Astellas Pharma Global Development	1	$16
Bristol Myers Squibb	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

IMFINZI$43,371
LUMAKRAS$2,744
BRAFTOVI$2,700
TUKYSA$1,375
DARZALEX$144
TALVEY$144
TECVAYLI$144
Avastin$125
Enhertu$125

How this compares

$88,520 in reported general payments places this provider in the 90th percentile of 67 medical oncology providers in Indiana.

See all medical oncology providers in Indiana →

Medicare billing

Part B allowed, 2024

$6,887

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prochlorperazine Maleate	12	$176
Potassium Chloride	12	$101
Furosemide	16	$38

Paid to pharmacies, not to this prescriber.

Other medical oncology in Indianapolis

Natraj AmmakkanavarIndianapolis$129K
Pablo BedanoIndianapolis$52K
Gregory SmithIndianapolis$46K
Ashwin VasudevamurthyIndianapolis$44K
Daniel SonnenburgIndianapolis$37K
Sumeet BhatiaIndianapolis$24K
Michael SlaughterIndianapolis$17K
Elsayed AlyIndianapolis$9K
Anuj AgarwalaIndianapolis$8K
Sead BeganovicIndianapolis$7K

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →